Ohzeki Takayuki, Fukasawa Satoshi, Komaru Atsushi, Namekawa Takeshi, Sato Yosuke, Takagi Kimiaki, Kobayashi Masayuki, Uemura Hirotsugu, Ichikawa Tomohiko, Ueda Takeshi
Prostate Center and Division of Urology, Chiba Cancer Center, Chiba, Japan.
Int J Urol. 2014 Oct;21(10):1065-8. doi: 10.1111/iju.12504. Epub 2014 Jun 15.
We report the adverse events and efficacy of traditional (4 weeks on 2 weeks off) and alternative sunitinib treatment schedules for Japanese patients with metastatic renal cell carcinoma. We retrospectively investigated 54 patients who received sunitinib for metastatic renal cell carcinoma between May 2006 and June 2012: 32 received a traditional treatment schedule and 22 received an alternative schedule. According to the Memorial Sloan-Kettering Cancer Center risk classification, five patients had favorable prognoses, 42 had intermediate prognoses and seven had poor prognoses. The mean observation periods were 16.3 and 20 months for the traditional and alternative schedule groups, respectively. Adverse events were significantly less common in the alternative schedule group, including most high-grade events. In the traditional and alternative schedule groups, median times to failure were 4.1 and 11.6 months (P = 0.040), median progression-free survival times were 4.1 and 11.3 months (P = 0.031), and median overall survival times were 12.0 and 32.1 months (P = 0.018), respectively. Each of these measures was better in the group of patients who received an alternative treatment schedule, suggesting that individualized changes to the sunitinib administration schedule can be effective.
我们报告了日本转移性肾细胞癌患者使用传统的（4周用药，2周停药）和替代性舒尼替尼治疗方案的不良事件及疗效。我们回顾性研究了2006年5月至2012年6月期间接受舒尼替尼治疗转移性肾细胞癌的54例患者：32例接受传统治疗方案，22例接受替代方案。根据纪念斯隆凯特琳癌症中心风险分类，5例患者预后良好，42例患者预后中等，7例患者预后较差。传统方案组和替代方案组的平均观察期分别为16.3个月和20个月。替代方案组的不良事件明显较少见，包括大多数高级别事件。在传统方案组和替代方案组中，至失败的中位时间分别为4.1个月和11.6个月（P = 0.040），无进展生存期的中位时间分别为4.1个月和11.3个月（P = 0.031），总生存期的中位时间分别为12.0个月和32.1个月（P = 0.018）。接受替代治疗方案的患者组在这些指标上均表现更佳，这表明对舒尼替尼给药方案进行个体化调整可能有效。
